Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group has entered into an exclusive license agreement (the "**Agreement**") with Cipla USA, Inc. ("**Cipla**") for the commercialization of the Group's Irinotecan Liposome Injection (the "**Product**") in the United States (the "**Territory**").

Under the terms of the Agreement, the Group agreed to grant an exclusive license to Cipla to commercialize the Product in the Territory. The Group will receive an upfront payment of US$15 million, and is also eligible to receive potential first commercial sale and regulatory milestone payments of up to US$25 million and potential additional commercial sales milestone payments of up to US$1,025 million, plus tiered double-digit royalties based on annual net sales of the Product in the Territory.

ABOUT THE PRODUCT

The Product is one of the representative innovative drugs independently developed under the liposome technology platform of the Group. The Product, a topoisomerase 1 inhibitor, is supplied as a sterile, white to slightly yellow opaque isotonic liposomal dispersion containing 43mg/10ml irinotecan. Irinotecan is currently used for the treatment of multiple solid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer and cervical cancer. It is a component in many combination regimens such as FOLFIRI or FOLFIRINOX for the treatment of these types of cancers.

ABOUT CIPLA

Cipla USA, Inc. is a pharmaceutical company headquartered in the United States which is committed to providing patients access to high-quality drugs.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 15 May 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.